Design, Development and Validation of Cell-based Bioassays MasterClass - EU edition

03-04 December, 2024

Development and validation of bioassays

Design, Development and Validation of Cell-based Bioassays MasterClass - EU edition

These assays should then be appropriately validated before performing the process performance qualification. This Master Class addresses common bioassay formats, as well as the development and validation of bioassays.

03-04 December, 2024, Virtual

Time Zone: UTC/GMT+1 /CET

GET THE AGENDA NOW

Pharma Online Masterclass

Overview

 

For the release of biotechnological products, potency is a mandatory critical quality attribute that manufacturers must evaluate to ensure it conforms to specifications for releasing drug substance and drug product batches. Cell-based bioassays are commonly used to determine potency. While binding assays, including non-cell-based assays, can be considered during early clinical development, regulatory bodies expect that cell-based bioassays reflecting the mechanism of action of the biotherapeutic be developed and implemented during late clinical development. These assays should then be appropriately validated before performing the process performance qualification. This Master Class addresses common bioassay formats, as well as the development and validation of bioassays.

#masterclass     #glceurope      #pharmaonlinetraining      #globalleadingconferences       #designanddevelopment      #validation       #cellbased     #bioassays

Trainer
Hervé Broly
Hervé Broly
Starting with an engineering degree in agriculture, followed by a PhD in plant physiology, I joined the Blood Transfusion Center (Lille, France) in 1982 where I implemented a unit for the development and manufacture of monoclonal antibodies against blood groups, blood proteins and viral antigens. In 1991, I took the position of Head of Process Development and Manufacturing at Sorebio (Martillac, France), a contract manufacturing organization specialized in the development and manufacture of monoclonal antibodies for clinical development. I took the lead of that company in 1998 after it was bought by Serono, a Swiss biotech company (Geneva, Switzerland) in 1994.In 2003, I moved to Serono in Geneva as Global Product Team Leader in charge of managing the development of a recombinant Ig-fusion protein for the treatment of autoimmune diseases, moving that product from Phase I to Phase III.

As of November 2006, Ive been appointed Vice-President, Head of Biotech Process Sciences at Merck-Serono, based in Vevey, Switzerland, in charge of developing and validating the manufacturing processes for biotechnological products. In that context, whereas Serono was mainly using perfusion processes for recombinant hormones and cytokines, we moved the company to large-scale manufacture of monoclonal antibodies using proprietary chemicallydefined cell culture media and feeds. After our participation to the FDAs pilot program on Quality by Design, the concepts described in ICH Q8(R2) and ICH Q11 were implemented in our approach to gain process understanding. It was concluded by issuing a modernized approach for process validation at Merck (Darmstadt, Germany). More recently, we have introduced advanced processes such as intensified fed-batch and continuous downstream processing.
Myléne Talabardon
Myléne Talabardon
With over 20 years of experience in the pharmaceutical industry, Mylène has a strong experience in process development, technology transfer and process validation. She obtained her PhD in biotechnology from The Ohio State University and her environmental engineering degree from the Swiss Federal Institute of Technology (EPFL). In 2001, she joined BiogenIdec in cell culture process department, focusing on antibody production from lab scale to manufacturing scale. In 2004, she has been appointed head of cell culture department at Merck Serono and started working in validation according to QbD for biotech products. After 2 years as CMC lead for a biosimilar product, she was nominated Process Validation Expert, and in this position, she developed the Global Process Validation strategy for the company according to European and FDA regulations for pharmaceuticals, and supported CMC teams in developing Process Validation plans for new biologics as well as for legacy products.

Who should attend imgRECOMMENDATION

Who should attend?


Bioassay development scientists
Bioassay validation personnel
Stability scientists
QA/QC personnel
Regulatory CMC
CMC project managers

Testimonial

Our success stories

"High attention to detail in course content and very well delivered"

Simon Halsey
Product Development Manager
Essentra Packaging
United Kingdom

Our success stories

"Very good training led by two knowledgeable and open experts. Excellent insight given on many complex topics. Interactive and highly useful"

Aurelie Vivicorsi
USP PD Team Manager
Celonic AG
Switzerland

Our success stories

"Great course, impressed with the knowledge of the trainers and ability to answer wide variety of questions!"

Emilia Szwej
Manager, Senior Investigator
MT Sword Laboratories (BMS)
Germany

About GLC

Global Leadership Conferences began as an ambitious dream by three founders ten years ago. Today its an international series of interactive events, exploring the hottest topics in critical fields. Each year, thousands of professionals join us to challenge the status quo and learn innovative ways to create new solutions in Finance, Pharmaceutical, HR, Health & Safety, and Energy.

know more >

13+

Years of experience

500+

Events organized

3,970

Speakers

23,714

Attendees

REQUEST AGENDA FORM
Download Full Agenda
Get the Agenda now for Additional Information, Detailed Program and Pricing

Name
Corporate email
Corporate phone
From where did you hear about the event?
Name of the GLC Representative (optional)
10+ participants interested from my team
E-mail consent
Privacy Policy

Other events you may like

Pharmacopeial compliance and marketing authorisations in Europe Masterclass - EU edition

Pharmacopeial compliance and marketing authorisations in Europe Masterclass - EU edition

15-16 October, 2024

Pharmacopoeias play a major role in quality standards for the manufacture and control of medicines in Europe and worldwide

Advanced Clinical Project Management MasterClass - US edition

Advanced Clinical Project Management MasterClass - US edition

15-18 October, 2024

Components of successful project management such as interaction between project activities and key decisions will be highlighted

13+

Years of experience

500+

Events organized

3,970

Speakers

23,714

Attendees

You’re in good company

deutsche bank logo e on logo kpmg logo merck logo roche logo siemens logo

Testimonial

Our success stories

"High attention to detail in course content and very well delivered"

Simon Halsey
Product Development Manager
Essentra Packaging
United Kingdom

Our success stories

"Very good training led by two knowledgeable and open experts. Excellent insight given on many complex topics. Interactive and highly useful"

Aurelie Vivicorsi
USP PD Team Manager
Celonic AG
Switzerland

Our success stories

"Great course, impressed with the knowledge of the trainers and ability to answer wide variety of questions!"

Emilia Szwej
Manager, Senior Investigator
MT Sword Laboratories (BMS)
Germany

Are you a registered client?

If you have questions, please reach us at

help@glceurope.com